416 related articles for article (PubMed ID: 22092535)
1. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
[TBL] [Abstract][Full Text] [Related]
2. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
4. IL-5- and eosinophil-mediated inflammation: from discovery to therapy.
Kouro T; Takatsu K
Int Immunol; 2009 Dec; 21(12):1303-9. PubMed ID: 19819937
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 5 in the link between the innate and acquired immune response.
Takatsu K; Kouro T; Nagai Y
Adv Immunol; 2009; 101():191-236. PubMed ID: 19231596
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
[TBL] [Abstract][Full Text] [Related]
8. IL-5 and eosinophilia.
Takatsu K; Nakajima H
Curr Opin Immunol; 2008 Jun; 20(3):288-94. PubMed ID: 18511250
[TBL] [Abstract][Full Text] [Related]
9. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor.
Monahan J; Siegel N; Keith R; Caparon M; Christine L; Compton R; Cusik S; Hirsch J; Huynh M; Devine C; Polazzi J; Rangwala S; Tsai B; Portanova J
J Immunol; 1997 Oct; 159(8):4024-34. PubMed ID: 9378992
[TBL] [Abstract][Full Text] [Related]
11. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.
Kolbeck R; Kozhich A; Koike M; Peng L; Andersson CK; Damschroder MM; Reed JL; Woods R; Dall'acqua WW; Stephens GL; Erjefalt JS; Bjermer L; Humbles AA; Gossage D; Wu H; Kiener PA; Spitalny GL; Mackay CR; Molfino NA; Coyle AJ
J Allergy Clin Immunol; 2010 Jun; 125(6):1344-1353.e2. PubMed ID: 20513525
[TBL] [Abstract][Full Text] [Related]
12. IL-5 and IL-5 receptor in asthma.
Kotsimbos AT; Hamid Q
Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():75-91. PubMed ID: 9698919
[TBL] [Abstract][Full Text] [Related]
13. [The influence of dexamethasone on mRNA expression of interleukin-5, interleukin-3 and granulocyte-macrophage colony-stimulating factor receptors in eosinophils of guinea pig asthma model].
Li Z; Wang C; Qian G
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Sep; 24(9):542-7. PubMed ID: 11758170
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5.
Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M
Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
16. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
Heinisch IV; Bizer C; Volgger W; Simon HU
J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
19. Haemopoietic processes in allergic disease: eosinophil/basophil development.
Gauvreau GM; Ellis AK; Denburg JA
Clin Exp Allergy; 2009 Sep; 39(9):1297-306. PubMed ID: 19622087
[TBL] [Abstract][Full Text] [Related]
20. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells.
Yamada T; Sun Q; Zeibecoglou K; Bungre J; North J; Kay AB; Lopez AF; Robinson DS
J Allergy Clin Immunol; 1998 May; 101(5):677-82. PubMed ID: 9600506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
